Value of 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scan versus diagnostic contrast computed tomography in initial staging of pediatric patients with lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 737-742

  Cheng, Gang ^a   Servaes, Sabah ^b   Zhuang, Hongming ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

FDG PET CT; Hodgkin disease; Lymphoma; Pediatric; Staging

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; CANCER SIZE; CANCER STAGING; CHILD; CHILDHOOD CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIAPHRAGM; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84879523095     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.727416     Document Type: Article

References (21)

1. Kumar R, Maillard I, Schuster SJ, et al. Utility of fluorodeoxyglucose- PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am 2004; 42: 1083-1100.
2. Cheng G, Servaes S, Alavi A, et al. FDG PET and PET/CT in the management of pediatric lymphoma patients. PET Clin 2008; 3: 621-634.
3. Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: A systematic review. Blood 2008; 111: 504-516.
4. Moskowitz CH, Zelenetz A, Schoder H. An update on the role of interim restaging FDG-PET in patients with Diffuse large B-cell lymphoma and Hodgkin lymphoma. J Natl Compr Canc Netw 2010; 8: 347-352.
5. Shankar A, Fiumara F, Pinkerton R. Role of FDG PET in the management of childhood lymphomas -case proven or is the jury still out? Eur J Cancer 2008; 44: 663-673.
6. Cheng G, Alavi A, Zhuang H. Clinical application of FDG PET/CT in pediatric lymphoma patients. PET Clin 2012; 7: 47-56.
7. Hicks RJ, Mac Manus MP, Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 2005; 35: 165-175.
8. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007; 110: 3507-3516.
9. Allen-Auerbach M, de Vos S, Czernin J. The impact of fluorodeoxyglucose- positron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin North Am 2008; 46: 199-211.
10. Montravers F, McNamara D, Landman-Parker J, et al. [ (18)F]FDG in childhood lymphoma: Clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002; 29: 1155-1165.
11. Hermann S, Wormanns D, Pixberg M, et al. Staging in childhood lymphoma: Differences between FDG-PET and CT. Nucl Med 2005; 44: 1-7.
12. Hernandez-Pampaloni M, Takalkar A, Yu JQ, et al. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol 2006; 36: 524-531.
13. London K, Cross S, Onikul E, et al. 18F-FDG PET/CT in paediatric lymphoma: Comparison with conventional imaging. Eur J Nucl Med Mol Imaging 2011; 38: 274-284.
14. Purz S, Mauz-Korholz C, Korholz D, et al. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. J Clin Oncol 2011; 29: 3523-3528.
15. Cheng G, Chen W, Chamroonrat W, et al. Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging 2011; 38: 1469-1476.
16. Cheng G, Servaes S, Chamroonrat W, et al. Non-Hodgkin's lymphoma of the bone and the liver without lymphadenopathy revealed on FDG-PET/CT. Clin Imaging 2010; 34: 476-479.
17. Ribrag V, Vanel D, Leboulleux S, et al. Prospective study of bone marrow infi ltration in aggressive lymphoma by three independent methods: Whole-body MRI, PET/CT and bone marrow biopsy. Eur J Radiol 2008; 66: 325-331.
18. Moulin-Romsee G, Hindié E, Cuenca X, et al. 18F-FDG PET/CT bone/bone marrow fi ndings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 2010; 37: 1095-1105.
19. Kabickova E, Sumerauer D, Cumlivska E, et al. Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease. Eur J Nucl Med Mol Imaging 2006; 33: 1025-1031.
20. Goethals I, Hoste P, De Vriendt C, et al. Time-dependent changes in 18F-FDG activity in the thymus and bone marrow following combination chemotherapy in paediatric patients with lymphoma. Eur J Nucl Med Mol Imaging 2010; 37: 462-467.
21. Sugawara Y, Fisher SJ, Zasadny KR, et al. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998; 16: 173-180.